The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI) Predicts Survival and Tolerance of Ibrutinib Therapy in Patients with CLL: A Multicenter Retrospective Cohort Study

被引：0
|
作者：
Gordon, Max J.
Kaempf, Andy
Sitlinger, Andrea
Salous, Tareq
Alqahtani, Hamood
Churnetski, Michael C.
Wisniewski, Paul
Rivera, Xavier Issac
Patel, Krish
Persky, Daniel O.
Cohen, Jonathon B.
Choi, Michael Y.
Hill, Brian T.
Shadman, Mazyar
Stephens, Deborah M.
Brander, Danielle M.
Park, Byung
Danilov, Alexey
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-136808
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] High Cell Death Rates at Start of Ibrutinib Therapy Predict for Deeper Remissions in Patients with Chronic Lymphocytic Leukemia (CLL)
    Kim, Ekaterina
    Sivina, Mariela
    Vaca, Alicia
    Ferrajoli, Alessandra
    Jain, Nitin
    Thompson, Philip A.
    Wierda, William G.
    Wodarz, Dominik
    Chiorazzi, Nicholas
    Burger, Jan A.
    BLOOD, 2022, 140 : 4140 - 4141
  • [42] A Multicenter, Phase IV Observational Study Of Ofatumumab In Chronic Lymphocytic Leukemia (CLL): A European Research Initiative On CLL (ERIC) Study
    Moreno, Carol
    Montillo, Marco
    Panayiotis, Panayiotidis
    Bloor, Adrian
    Dupuis, Jehan
    Schuh, Anna
    Norin, Stefan
    Geisler, Christian H.
    Hillmen, Peter
    Doubek, Michael
    Obrtlikova, Petra
    Laurenti, Luca
    Stilgenbauer, Stephan
    Smolej, Lukas
    Ghia, Paolo
    Cymbalista, Florence
    Jaeger, Ulrich
    Stavroyianni, Niki
    Carrington, Patrick
    Zouabi, Hamadi
    Leblond, Veronique
    Carlos Gomez, Juan
    Marasca, Roberto
    Musuraca, Gerardo
    Rigacci, Luigi
    Farina, Lucia
    Paolini, Rossella
    Pospisilova, Sarka
    Kimby, Eva
    Bradley, Colm
    Montserrat, Emili
    BLOOD, 2013, 122 (21)
  • [43] Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice
    Finnes, Heidi D.
    Chaffee, Kari G.
    Call, Timothy G.
    Ding, Wei
    Kenderian, Saad S.
    Bowen, Deborah A.
    Conte, Michael
    McCullough, Kristen B.
    Merten, Julianna A.
    Bartoo, Gabriel T.
    Smith, Matthew D.
    Leis, Jose
    Chanan-Khan, Asher
    Schwager, Susan M.
    Slager, Susan L.
    Kay, Neil E.
    Shanafelt, Tait D.
    Parikh, Sameer A.
    LEUKEMIA & LYMPHOMA, 2017, 58 (06) : 1376 - 1383
  • [44] Survival outcomes after initial infused therapy for elderly chronic lymphocytic leukemia (CLL) patients.
    Danese, M.
    Griffiths, R.
    Gleeson, M.
    Satram-Hoang, S.
    Knopf, K. B.
    Mikhael, J.
    Reyes, C. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] The effect of initial therapy choice in determining long term survival in patients with chronic lymphocytic leukemia (CLL).
    Tam, Constantine S.
    Wen, Sijin
    Do, Kim-Anh
    Lerner, Susan
    Wierda, William G.
    O'Brien, Susan
    Keating, Michael J.
    BLOOD, 2006, 108 (11) : 332B - 332B
  • [46] Comparative Study of Cardiovascular Co-Morbidities between Ibrutinib and Non-Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL) Patients
    Nero, Damion
    Chung, Jessica
    Mato, Anthony R.
    Kish, Jonathan
    Nabhan, Chadi
    BLOOD, 2017, 130
  • [47] Chronic Lymphocytic Leukemia International Prognostic INDEX (CLL-IPI) Predicts Prognosis of CLL: A Systematic Review and Meta-Analysis
    Molica, Stefano
    Giannarelli, Diana
    Levato, Luciano
    Mirabelli, Rosana
    Shanafelt, Tait D.
    BLOOD, 2017, 130
  • [48] Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index (CLL-IPI).
    Wang, Yucai
    Achenbach, Sara J.
    Rabe, Kari G.
    Shanafelt, Tait D.
    Call, Timothy
    Ding, Wei
    Kenderian, Saad
    Muchtar, Eli
    Leis, Jose Francisco
    Koehler, Amber
    Schwager, Susan M.
    Cerhan, James Robert
    Slager, Susan L.
    Kay, Neil E.
    Parikh, Sameer Ashok
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [49] Randomized Trial of Ibrutinib Versus Ibrutinib Plus Rituximab (Ib plus R) in Patients with Chronic Lymphocytic Leukemia (CLL)
    Burger, Jan A.
    Sivina, Mariela
    Ferrajoli, Alessandra
    Jain, Nitin
    Kim, Ekaterina
    Kadia, Tapan
    Estrov, Zeev
    Gonzalez, Graciela Nogueras
    Huang, Xuelin
    Ohanian, Maro
    Andreeff, Michael
    Thomas, Mathew
    Alexander-Williams, Lynette
    Kantarjian, Hagop M.
    O'Brien, Susan M.
    Wierda, William G.
    Keating, Michael J.
    BLOOD, 2017, 130
  • [50] Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study
    Van Den Neste, Eric
    Cazin, Bruno
    Janssens, Ann
    Gonzalez-Barca, Eva
    Jose Terol, Maria
    Levy, Vincent
    Perez de Oteyza, Jaime
    Zachee, Pierre
    Saunders, Andrew
    de Frias, Merce
    Campas, Clara
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (03) : 581 - 591
12345